These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 38531118)

  • 21. Initiation of emicizumab prophylaxis in an infant with haemophilia A and subdural haemorrhage.
    Bush KA; Lucas TL; Haley KM; Thornburg CD
    Haemophilia; 2020 Nov; 26(6):e353-e355. PubMed ID: 32892446
    [No Abstract]   [Full Text] [Related]  

  • 22. Interferences by factor VIII and lupus anticoagulant in the modified one-stage assay for emicizumab.
    Habay C; Auditeau C; Blandinières A; Bentounes NK; Lavenu-Bombled C; Harroche A; Bally C; Frenzel L; Borgel D; Lasne D
    Haemophilia; 2023 Nov; 29(6):1661-1664. PubMed ID: 37751318
    [No Abstract]   [Full Text] [Related]  

  • 23. Anti-idiotype monoclonal antibodies against emicizumab enable accurate procoagulant and anticoagulant assays, irrespective of the test base, in the presence of emicizumab.
    Ogiwara K; Furukawa S; Shinohara S; Tabuchi Y; Arai N; Noguchi-Sasaki M; Soeda T; Shima M; Nogami K
    Haemophilia; 2023 Jan; 29(1):329-335. PubMed ID: 36137299
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bridging the Missing Link with Emicizumab: A Bispecific Antibody for Treatment of Hemophilia A.
    Gelbenegger G; Schoergenhofer C; Knoebl P; Jilma B
    Thromb Haemost; 2020 Oct; 120(10):1357-1370. PubMed ID: 32717759
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparisons of global coagulation potential and bleeding episodes in emicizumab-treated hemophilia A patients and mild hemophilia A patients.
    Nakajima Y; Mizumachi K; Shimonishi N; Furukawa S; Yada K; Ogiwara K; Takeyama M; Shima M; Nogami K
    Int J Hematol; 2022 Apr; 115(4):489-498. PubMed ID: 35043383
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects and Interferences of Emicizumab, a Humanised Bispecific Antibody Mimicking Activated Factor VIII Cofactor Function, on Coagulation Assays.
    Adamkewicz JI; Chen DC; Paz-Priel I
    Thromb Haemost; 2019 Jul; 119(7):1084-1093. PubMed ID: 31064025
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Idarucizumab for dabigatran overdose in a child.
    Shapiro S; Bhatnagar N; Khan A; Beavis J; Keeling D
    Br J Haematol; 2018 Feb; 180(3):457-459. PubMed ID: 27734469
    [No Abstract]   [Full Text] [Related]  

  • 28. Surgery with emicizumab prophylaxis for two paediatric patients with severe haemophilia A with inhibitors.
    Lockhart M; Tardy-Poncet B; Montmartin A; Noyel P; Thouvenin S; Berger C
    Pediatr Blood Cancer; 2021 Jul; 68(7):e29041. PubMed ID: 33851509
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Emicizumab for routine prophylaxis to prevent bleeding episodes in patients with hemophilia A.
    Díaz-Ricart M; Isola IM; Escolar G
    Drugs Today (Barc); 2018 Oct; 54(10):591-600. PubMed ID: 30398480
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The potential role of emicizumab prophylaxis in severe von Willebrand disease.
    Barg AA; Avishai E; Budnik I; Brutman TB; Tamarin I; Dardik R; Bashari D; Misgav M; Lubetsky A; Lalezari S; Livnat T; Kenet G
    Blood Cells Mol Dis; 2021 Mar; 87():102530. PubMed ID: 33341070
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of emicizumab on global coagulation assays for plasma supplemented with apixaban or argatroban.
    Tripodi A; Chantarangkul V; Padovan L; Clerici M; Scalambrino E; Peyvandi F
    J Thromb Thrombolysis; 2020 Apr; 49(3):413-419. PubMed ID: 31728842
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Emicizumab treatment: Impact on coagulation tests and biological monitoring of haemostasis according to clinical situations (BIMHO group proposals).
    Nougier C; Jeanpierre E; Ternisien C; Proulle V; Hezard N; Pouplard C; Lasne D;
    Eur J Haematol; 2020 Dec; 105(6):675-681. PubMed ID: 32668090
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Thromboprophylaxis in a patient with COVID-19 and severe hemophilia A on emicizumab prophylaxis.
    Rivas-Pollmar MI; Álvarez-Román MT; Butta-Coll NV; Martín Salces M; García-Barcenilla S; Jiménez-Yuste V
    J Thromb Haemost; 2020 Sep; 18(9):2202-2204. PubMed ID: 32526092
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The factor VIII heavy chain improves emicizumab-tenase assembly to enhance the factor VIII-mimicking cofactor activity.
    Minami H; Nogami K; Soeda T; Kitazawa T; Hattori K; Shima M
    Thromb Res; 2018 Jun; 166():77-79. PubMed ID: 29684725
    [No Abstract]   [Full Text] [Related]  

  • 35. Emicizumab Augments Thrombus Formation in Whole Blood from Patients with Hemophilia A under High Shear Flow Conditions.
    Yaoi H; Shida Y; Kitazawa T; Shima M; Nogami K
    Thromb Haemost; 2021 Mar; 121(3):279-286. PubMed ID: 32906155
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Switching to emicizumab: A prospective surveillance study in haemophilia A subjects with inhibitors.
    Dubé E; Merlen C; Bonnefoy A; Pilon J; Zourikian N; Gauthier J; St-Louis J; Rivard GÉ
    Haemophilia; 2023 Jan; 29(1):348-351. PubMed ID: 36315386
    [No Abstract]   [Full Text] [Related]  

  • 37. Safety and efficacy of emicizumab and other novel agents in newborns and infants.
    Pierce GF; Hart DP; Kaczmarek R;
    Haemophilia; 2019 Sep; 25(5):e334-e335. PubMed ID: 31361382
    [No Abstract]   [Full Text] [Related]  

  • 38. Emicizumab-kxwh: First Global Approval.
    Scott LJ; Kim ES
    Drugs; 2018 Feb; 78(2):269-274. PubMed ID: 29357074
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A boy with joint pain associated with emicizumab treatment: The importance of plasma level measurement.
    Hooimeijer HL; Lukens MV; Verhagen MV; Meijer K; Stein-Wit MA; Tamminga RYJ
    Haemophilia; 2020 May; 26(3):e138-e140. PubMed ID: 32297683
    [No Abstract]   [Full Text] [Related]  

  • 40. Heterogeneous coagulant potential of emicizumab in neonatal factor VIII-deficient plasma.
    Takeyama M; Furukawa S; Onishi T; Noguchi-Sasaki M; Shima M; Nogami K
    Pediatr Blood Cancer; 2022 Jul; 69(7):e29731. PubMed ID: 35441786
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.